KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) Cost of Revenue (2018 - 2025)

Historic Cost of Revenue for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $23.5 million.

  • Adaptive Biotechnologies' Cost of Revenue rose 1420.37% to $23.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.7 million, marking a year-over-year increase of 772.71%. This contributed to the annual value of $84.8 million for FY2024, which is 431.25% down from last year.
  • As of Q3 2025, Adaptive Biotechnologies' Cost of Revenue stood at $23.5 million, which was up 1420.37% from $23.6 million recorded in Q2 2025.
  • In the past 5 years, Adaptive Biotechnologies' Cost of Revenue ranged from a high of $26.7 million in Q4 2021 and a low of $20.3 million during Q2 2024
  • Moreover, its 5-year median value for Cost of Revenue was $23.0 million (2025), whereas its average is $22.9 million.
  • As far as peak fluctuations go, Adaptive Biotechnologies' Cost of Revenue skyrocketed by 7237.11% in 2021, and later tumbled by 1490.45% in 2024.
  • Adaptive Biotechnologies' Cost of Revenue (Quarter) stood at $26.7 million in 2021, then dropped by 11.16% to $23.7 million in 2022, then dropped by 7.63% to $21.9 million in 2023, then dropped by 1.51% to $21.6 million in 2024, then grew by 8.78% to $23.5 million in 2025.
  • Its last three reported values are $23.5 million in Q3 2025, $23.6 million for Q2 2025, and $23.0 million during Q1 2025.